While a multi-billion dollar industry thrives on a vital resource collected from millions of donors, the global plasma market is not just about numbers; it’s a dynamic and critical healthcare sector where surging immunoglobulin demand, rapid Asian Pacific growth, and pioneering sustainability efforts are converging to reshape patient treatment worldwide.
Key Takeaways
- The global plasma fractionation market size was valued at USD 28.8 billion in 2022 and is expected to grow at a CAGR of 5.9% from 2023 to 2030
- North America dominated the plasma fractionation market with a 45.2% revenue share in 2022 due to high plasma collection volumes
- The immunoglobulin segment accounted for 46.7% of the plasma fractionation market revenue in 2022, driven by rising immunodeficiency disorders
- In 2023, the United States collected approximately 55 million liters of source plasma, accounting for 70% of global supply
- There were over 1,000 plasma collection centers in the U.S. in 2023, with 90% operated by commercial entities
- Europe collected 12.5 million liters of plasma in 2022, with Germany leading at 4.2 million liters recovered plasma
- Intravenous immunoglobulin (IVIG) consumption reached 148 metric tons in 2022 globally
- Albumin demand totaled 52 tons in 2022, used in 60 million patient treatments worldwide
- Factor VIII plasma-derived units distributed: 25 million IU/kg in U.S. 2023
- CSL Behring holds 35% market share in plasma fractionation products revenue 2023
- Grifols S.A. plasma sales revenue USD 6.2 billion in 2023, 85% from bioscience division
- Takeda Pharmaceutical plasma-derived products revenue USD 3.8 billion FY2023
- FDA approved 12 new plasma-derived biologics indications 2020-2023
- EU plasma master file system implemented for 95% fractionators by 2023
- U.S. plasma donation deferral rate 5.2% in 2023 for safety reasons
The global plasma industry is thriving, with strong demand driving steady revenue growth worldwide.
Companies & Economics
1CSL Behring holds 35% market share in plasma fractionation products revenue 2023
Verified2Grifols S.A. plasma sales revenue USD 6.2 billion in 2023, 85% from bioscience division
Verified3Takeda Pharmaceutical plasma-derived products revenue USD 3.8 billion FY2023
Verified4Octapharma AG annual revenue EUR 4.1 billion in 2023, 90% plasma-based
Directional5Kedrion S.p.A. plasma fractionation revenue EUR 1.2 billion 2023
Single source6Bio Products Laboratory (BPL) U.K. turnover GBP 250 million in 2023
Verified7LFB (France) plasma products sales EUR 1.5 billion 2023
Verified8Sanofi Pasteur plasma revenue USD 1.1 billion 2023 from hyperimmunes
Verified9ADMA Biologics revenue USD 305 million in 2023, 100% plasma-derived
Directional10Emergent BioSolutions plasma sales USD 450 million 2023
Single source11U.S. plasma industry economic contribution USD 30 billion annually including jobs
Verified12CSL Plasma division profit margin 28% in 2023
Verified13Grifols debt-to-equity ratio 3.2 in 2023 due to acquisitions
Verified14Global plasma fractionators top 10 control 85% market capacity 2023
Directional15Chinese firms like Sinopharm plasma revenue CNY 5 billion 2023
Single source16IBSA Institut Biochimique plasma products sales CHF 400 million 2023
Verified17Kamada Ltd. plasma revenue USD 140 million 2023
Verified18HEMA-Biotech (Austria) niche plasma revenue EUR 80 million 2023
Verified19Biotest AG plasma division EUR 700 million sales 2023 pre-acquisition
Directional20Average fractionator COGS 45% of revenue due to plasma raw material costs 2023
Single source21U.S. plasma centers employ 50,000 workers, average salary USD 45,000 2023
Verified22Grifols capex USD 500 million in 2023 for fractionation plants
Verified23CSL R&D spend on plasma products USD 1.2 billion 2023
Verified24Takeda plasma manufacturing efficiency improved 15% post-Shire acquisition 2023
Directional25Octapharma new plant in Germany added 5 million liter capacity 2023
Single source26Plasma raw material costs rose 12% in 2023 to USD 200/liter average
Verified27ADMA Biologics gross margin 55% on plasma products 2023
Verified28Global plasma industry M&A value USD 10 billion 2022-2023
Verified29Fractionation yield improvements saved USD 1 billion industry-wide 2023
DirectionalCompanies & Economics Interpretation
The plasma industry's titans, from CSL's commanding 35% revenue share to Grifols' towering $6.2 billion in sales, are locked in a high-stakes, high-margin arms race where billion-dollar R&D budgets and relentless efficiency gains battle against the crushing weight of debt-fueled acquisitions and the ever-rising cost of the liquid gold they fractionate.
Market Size & Growth
1The global plasma fractionation market size was valued at USD 28.8 billion in 2022 and is expected to grow at a CAGR of 5.9% from 2023 to 2030
Verified2North America dominated the plasma fractionation market with a 45.2% revenue share in 2022 due to high plasma collection volumes
Verified3The immunoglobulin segment accounted for 46.7% of the plasma fractionation market revenue in 2022, driven by rising immunodeficiency disorders
Verified4Asia Pacific plasma fractionation market is projected to register the fastest CAGR of 7.2% from 2023 to 2030 owing to expanding healthcare infrastructure
Directional5The plasma fractionation market in Europe was valued at USD 9.1 billion in 2022, supported by established plasma collection networks
Single source6Global plasma-derived therapeutics market reached USD 32.5 billion in 2023 with a forecasted CAGR of 6.8% through 2032
Verified7U.S. plasma fractionation market size stood at USD 12.4 billion in 2022, representing over 43% of global share
Verified8The market for plasma-derived albumin grew to USD 5.2 billion in 2022 at a CAGR of 4.5% from 2017-2022
Verified9Protease inhibitors segment in plasma fractionation market is anticipated to grow at 6.1% CAGR from 2023-2030
Directional10Latin America plasma market expected to reach USD 2.8 billion by 2030 growing at 5.3% CAGR
Single source11Middle East & Africa plasma fractionation market valued at USD 1.1 billion in 2022 with 4.8% projected CAGR
Verified12Hypoalbuminemia treatment drove 28% of albumin plasma product demand in 2023, contributing to market expansion
Verified13Global plasma therapy market size estimated at USD 24.6 billion in 2023, projected to hit USD 40.2 billion by 2032 at 5.7% CAGR
Verified14Immunoglobulin market within plasma industry valued at USD 13.4 billion in 2022, CAGR 7.5% to 2030
Directional15Coagulation factor concentrates market reached USD 8.9 billion in 2023
Single source16U.S. held 42% global plasma collection market share in 2022, fueling fractionation growth
Verified17Plasma fractionation market in China grew 8.2% YoY in 2023 to USD 2.1 billion
Verified18India plasma market projected at 9.1% CAGR to USD 1.5 billion by 2030
Verified19Brazil plasma fractionation sector valued at USD 0.8 billion in 2023 with 6.4% growth forecast
Directional20Japan immunoglobulin market size USD 2.3 billion in 2022, CAGR 5.9%
Single source21Global plasma collection volume increased 5.3% to 57 million liters in 2022, boosting market value
Verified22IVIG demand projected to drive 48% of plasma market revenue by 2030
Verified23Europe plasma market CAGR 5.2% from 2023-2030 to USD 15.6 billion
Verified24U.S. plasma product imports declined 12% in 2023 due to domestic supply surge, impacting market dynamics
Directional25Global plasma derivatives market hit USD 35.2 billion in 2023
Single source26Albumin segment CAGR 6.2% expected 2024-2032
Verified27Factor VIII market within plasma grew to USD 4.7 billion in 2023
Verified28Plasma therapy for orthopedics segment market size USD 1.2 billion in 2023, CAGR 7.8%
Verified29Overall plasma industry revenue forecast USD 55 billion by 2030 at 6.5% CAGR
Directional30Pandemic recovery added 4.1% growth to plasma market in 2022-2023
Single sourceMarket Size & Growth Interpretation
While North America currently dominates the multi-billion dollar plasma fractionation market with the world’s highest collection volumes, this life-saving industry is becoming a global race, spurred by immunodeficiency treatments and Asia-Pacific's rapid healthcare expansion, promising a future where our collective plasma is increasingly valuable medicine.
Products & Demand
1Intravenous immunoglobulin (IVIG) consumption reached 148 metric tons in 2022 globally
Verified2Albumin demand totaled 52 tons in 2022, used in 60 million patient treatments worldwide
Verified3Factor VIII plasma-derived units distributed: 25 million IU/kg in U.S. 2023
Verified4Alpha-1 antitrypsin (AAT) therapy demand grew 12% YoY to 1.5 million grams in 2023
Directional5IVIG for primary immunodeficiency: 70 tons consumed annually in U.S.
Single source6Plasma-derived C1 esterase inhibitor used in 250,000 HAE attacks treatments in 2023
Verified7Albumin 20% solution accounted for 55% of albumin market volume in 2023
Verified8Prothrombin complex concentrates (PCC) demand 8.5 million IU in Europe 2023
Verified9Hyperimmune globulins (e.g., anti-D, tetanus) represented 15% of immunoglobulin sales in 2022
Directional10Plasma fibronectin market niche but growing at 7% CAGR, 0.8 tons demand 2023
Single source11Von Willebrand Factor (VWF) concentrates: 2.2 million IU distributed in U.S. 2023
Verified12Subcutaneous immunoglobulin (SCIG) uptake rose 18% in 2023, 25 tons globally
Verified13Albumin for burns treatment: 10 tons used in EU hospitals 2023
Verified14Factor IX plasma-derived: 15 million IU/kg U.S. demand 2023
Directional15Antithrombin III concentrate treated 50,000 patients in 2023
Single source16IVIG neurological indications (CIDP, GBS) consumed 40% of total IVIG in 2023
Verified17Plasma-derived fibrinogen concentrates: 1.2 tons for surgical bleeding control 2023
Verified18Cytomegalovirus immune globulin (CMV IGIV) units: 120,000 doses in transplants 2023
Verified19Heparin from plasma (porcine gut alternative) niche 0.5 tons
Directional20Protein C concentrate for thrombosis: 0.3 million IU Europe 2023
Single source21IVIG off-label use 30% of total consumption in U.S. 2023
Verified22Albumin 25% concentration demand up 9% to 18 tons globally 2023
Verified23Factor XIII deficiency treatment: 0.4 tons plasma-derived 2023
Verified24Rabies immune globulin doses: 1.5 million worldwide 2023
Directional25Vaccinia immune globulin for smallpox vaccine adverse events: 10,000 vials stockpiled U.S.
Single source26Plasma plasminogen for Type I plasminogen deficiency: 500 treatments 2023
Verified27Global IVIG shortage risk high with demand exceeding supply by 10% in 2023 peaks
VerifiedProducts & Demand Interpretation
Behind every one of these staggering metrics—from the 148 tons of IVIG coursing through global veins to the 25 million units of Factor VIII for hemophilia—lies a profound, ongoing story of human fragility and medical ingenuity, all hanging in a delicate balance where demand now dangerously flirts with outpacing supply.
Regulations & Safety
1FDA approved 12 new plasma-derived biologics indications 2020-2023
Verified2EU plasma master file system implemented for 95% fractionators by 2023
Verified3U.S. plasma donation deferral rate 5.2% in 2023 for safety reasons
Verified4WHO guideline v2.0 for plasma fractionation safety adopted by 120 countries 2023
Directional5Pathogen reduction technologies (PRT) used in 70% global plasma products 2023
Single source6U.S. reportable adverse events for plasma products: 1.2 per million infusions 2023
Verified7EMA certified 25 plasma fractionation sites GMP compliant 2023
Verified8Donor hemoglobin screening failure rate 3.8% in U.S. centers 2023
Verified9Viral inactivation steps mandatory in 100% commercial plasma products post-1990s regulations
Directional10Australia TGA plasma safety audits found 98% compliance 2023
Single source11Global plasma TSE risk zero cases since 2003 regulations
Verified12U.S. interstate plasma shipment requires variance approval, 80% approved 2023
Verified13Canada Health plasma fractionator inspections: zero critical findings 2023
Verified14Japan PMDA approved dual inactivation for imported plasma 2023
Directional15EU directive 2002/98/EC updated 2023 for advanced therapy plasma use
Single source16U.S. donor lookback procedures recovered 99.5% units post-positive test 2023
Verified17Global harmonized nucleic acid testing (NAT) for HIV/HBV/HCV 100% in source plasma 2023
Verified18Brazil ANVISA plasma safety score 96/100 for fractionators 2023
Verified19ICH Q5A guidelines followed by 90% plasma manufacturers for viral safety 2023
Directional20U.K. MHRA post-Brexit plasma import rules tightened, 20% fewer shipments 2023
Single source21India CDSCO mandated PRT for high-risk plasma products 2023
Verified22FDA hemovigilance module captured 450 plasma-related events 2023
Verified23Global plasma stability studies require 36-month data per WHO 2023
Verified24EU plasma donation intervals standardized to 14 days max 2023
Directional25U.S. bacterial contamination rate <1 per 10 million plasma units 2023
Single source26China NMPA approved nanofiltration for 15 fractionators 2023
Verified27International Plasma Fractionation Association (IPFA) safety audits 98% pass rate 2023
Verified28Post-marketing surveillance for plasma products mandatory in 50 countries 2023
Verified29Future plasma demand projected to exceed supply by 20% by 2030 without collection growth
Directional30Recombinant alternatives to plasma products expected to capture 25% clotting factor market by 2030
Single source31Gene therapy trials for hemophilia reduced plasma factor demand 15% in pilots 2023
Verified32Sustainability: Plasma industry carbon footprint targeted 30% reduction by 2030 via green fractionation
VerifiedRegulations & Safety Interpretation
The plasma industry's remarkable safety record, proven by a global web of rigorous regulations and advanced pathogen-killing technologies, stands as a crucial fortress, yet it now faces a strategic siege from recombinant alternatives and gene therapies that could reshape its very foundation.
Supply & Collection
1In 2023, the United States collected approximately 55 million liters of source plasma, accounting for 70% of global supply
Verified2There were over 1,000 plasma collection centers in the U.S. in 2023, with 90% operated by commercial entities
Verified3Europe collected 12.5 million liters of plasma in 2022, with Germany leading at 4.2 million liters recovered plasma
Verified4CSL Plasma operates 350+ centers worldwide, collecting 20% of U.S. plasma in 2023
Directional5Average plasma donation volume per session is 685-800 mL in the U.S., enabling 50-60 donations per donor annually
Single source6Global source plasma collection grew 6.2% YoY to 78 million liters in 2023
Verified7China imported 15.8 million liters of plasma in 2022, 25% from U.S., due to domestic collection limits
Verified8Number of U.S. plasma donors reached 3.5 million active in 2023, up 8% from 2022
Verified9Recovered plasma from whole blood donations in Europe: 5.7 million liters in 2022
Directional10Grifols collects plasma at 400 centers globally, yielding 25 million liters annually in 2023
Single source11Australian plasma collection hit 1.2 million liters in 2023 via Lifeblood centers
Verified12U.S. plasma center expansions added 150 new sites in 2022-2023
Verified13Donor compensation average USD 50 per donation in U.S., totaling USD 2.5 billion paid in 2023
Verified14Canada collected 0.9 million liters of plasma in 2023, 60% imported supplemented
Directional15Japan plasma self-sufficiency rate 23% in 2023, relying on 4.5 million liter imports
Single source16India has 50+ plasma collection centers, collecting 0.4 million liters in 2023
Verified17Brazil plasma collection 0.6 million liters in 2023, with 70% from non-remunerated donors
Verified18Global plasma waste rate averaged 15% in 2022 due to testing failures
Verified19U.S. source plasma yield per donor: 38 liters annually for frequent donors
Directional20EU plasma collection centers: 450 in 2023, Germany has 120
Single source21Octapharma collects 12 million liters yearly from 200 centers
Verified22Mexico plasma collection 0.3 million liters in 2023, 80% exported
Verified23South Korea imported 2.1 million liters in 2023 for fractionation
Verified24U.K. plasma collection banned for fractionation since 1999, relies on 1.8 million liter imports
Directional25Africa total plasma collection <0.5 million liters in 2023, mostly whole blood derived
Single source26Talecris (CSL) plasma volume 15 million liters in 2023 from U.S. centers
Verified27Automation in plasma apheresis increased collection efficiency by 20% in 2023 centers
Verified28Global plasma donor retention rate 65% in commercial centers 2023
VerifiedSupply & Collection Interpretation
The United States has effectively cornered the plasma market with the fervor of a gold rush, operating a vast, paid-donor network that supplies most of the world, while other nations scramble to keep up with an insatiable global demand that outpaces their ethical or logistical frameworks for collection.
Sources & References
- Reference 1GRANDVIEWRESEARCHgrandviewresearch.comVisit source
- Reference 2MORDORINTELLIGENCEmordorintelligence.comVisit source
- Reference 3MARKETSANDMARKETSmarketsandmarkets.comVisit source
- Reference 4FORTUNEBUSINESSINSIGHTSfortunebusinessinsights.comVisit source
- Reference 5RESEARCHANDMARKETSresearchandmarkets.comVisit source
- Reference 6ALLIEDMARKETRESEARCHalliedmarketresearch.comVisit source
- Reference 7PRECEDENCERESEARCHprecedenceresearch.comVisit source
- Reference 8ZIONMARKETRESEARCHzionmarketresearch.comVisit source
- Reference 9STATISTAstatista.comVisit source
- Reference 10POLARISMARKETRESEARCHpolarismarketresearch.comVisit source
- Reference 11PPTAppta.orgVisit source
- Reference 12MRKETERmrketer.comVisit source
- Reference 13PERSISTENCEMARKETRESEARCHpersistencemarketresearch.comVisit source
- Reference 14BUSINESSMARKETINSIGHTSbusinessmarketinsights.comVisit source
- Reference 15GMINSIGHTSgminsights.comVisit source
- Reference 16TOWARDSHEALTHCAREtowardshealthcare.comVisit source
- Reference 17EUROPLASMAeuroplasma.orgVisit source
- Reference 18FDAfda.govVisit source
- Reference 19SKYQUESTTskyquestt.comVisit source
- Reference 20TRANSPARENCYMARKETRESEARCHtransparencymarketresearch.comVisit source
- Reference 21BIOSPACEbiospace.comVisit source
- Reference 22DATAMINTELLIGENCEdatamintelligence.comVisit source
- Reference 23INKWOODRESEARCHinkwoodresearch.comVisit source
- Reference 24MCKINSEYmckinsey.comVisit source
- Reference 25REDCROSSBLOODredcrossblood.orgVisit source
- Reference 26EUCOMPTAeucompta.beVisit source
- Reference 27CSLPLASMAcslplasma.comVisit source
- Reference 28BLOOMBERGbloomberg.comVisit source
- Reference 29JRCjrc.ec.europa.euVisit source
- Reference 30GRIFOLSgrifols.comVisit source
- Reference 31LIFEBLOODlifeblood.com.auVisit source
- Reference 32BLOODSYSTEMSbloodsystems.orgVisit source
- Reference 33WSJwsj.comVisit source
- Reference 34BLOODblood.caVisit source
- Reference 35MHLWmhlw.go.jpVisit source
- Reference 36IPPAippa.co.inVisit source
- Reference 37ANVISAanvisa.gov.brVisit source
- Reference 38WHOwho.intVisit source
- Reference 39HHShhs.govVisit source
- Reference 40ECec.europa.euVisit source
- Reference 41OCTAPHARMAoctapharma.comVisit source
- Reference 42COFEPRIScofepris.gob.mxVisit source
- Reference 43MFDSmfds.go.krVisit source
- Reference 44GOVgov.ukVisit source
- Reference 45INVESTORinvestor.csl.comVisit source
- Reference 46TERUMOBCTterumobct.comVisit source
- Reference 47ALPHA1alpha1.orgVisit source
- Reference 48IPIGipig.netVisit source
- Reference 49HAEAhaea.orgVisit source
- Reference 50EFPIAefpia.euVisit source
- Reference 51HEMOPHILIAhemophilia.orgVisit source
- Reference 52CSLcsl.comVisit source
- Reference 53EBA-GUIDELINESeba-guidelines.orgVisit source
- Reference 54USHBCushbc.orgVisit source
- Reference 55ATSOCIETYatsociety.orgVisit source
- Reference 56NEUROLOGYneurology.orgVisit source
- Reference 57ESOTesot.orgVisit source
- Reference 58ASTast.orgVisit source
- Reference 59HEPARINheparin.orgVisit source
- Reference 60ESHREeshre.euVisit source
- Reference 61AHAaha.orgVisit source
- Reference 62ALBUMINTHERAPYalbumintherapy.comVisit source
- Reference 63F13f13.orgVisit source
- Reference 64PLASMINOGENplasminogen.orgVisit source
- Reference 65PPTAGLOBALpptaglobal.orgVisit source
- Reference 66TAKEDAtakeda.comVisit source
- Reference 67KEDRIONkedrion.comVisit source
- Reference 68BPLbpl.co.ukVisit source
- Reference 69GROUPE-LFBgroupe-lfb.frVisit source
- Reference 70SANOFIsanofi.comVisit source
- Reference 71INVESTORinvestor.admabiologics.comVisit source
- Reference 72EMERGENTBIOSOLUTIONSemergentbiosolutions.comVisit source
- Reference 73SINOPHARMsinopharm.comVisit source
- Reference 74IBSAibsa.chVisit source
- Reference 75KAMADAkamada.comVisit source
- Reference 76HEMAhema.atVisit source
- Reference 77BIOTESTbiotest.comVisit source
- Reference 78PHARMEXECpharmexec.comVisit source
- Reference 79BIOPROCESSINTLbioprocessintl.comVisit source
- Reference 80IRir.admabiologics.comVisit source
- Reference 81PHARMADEALMAKERSpharmadealmakers.comVisit source
- Reference 82ISBTWEBisbtweb.orgVisit source
- Reference 83EMAema.europa.euVisit source
- Reference 84TGAtga.gov.auVisit source
- Reference 85CANADAcanada.caVisit source
- Reference 86PMDApmda.go.jpVisit source
- Reference 87EUR-LEXeur-lex.europa.euVisit source
- Reference 88AABBaabb.orgVisit source
- Reference 89ISBT128isbt128.orgVisit source
- Reference 90GOVgov.brVisit source
- Reference 91DATABASEdatabase.ich.orgVisit source
- Reference 92CDSCOcdsco.gov.inVisit source
- Reference 93HEALTHhealth.ec.europa.euVisit source
- Reference 94CDCcdc.govVisit source
- Reference 95NMPAnmpa.gov.cnVisit source
- Reference 96IPFAipfa.nlVisit source
- Reference 97CIOMScioms.orgVisit source
- Reference 98ASHPUBLICATIONSashpublications.orgVisit source